Gut dysbiosis in antithrombotic-related bleeding is explained by clinical confounders rather than bleeding itself: a case-control study

The human gut is home to trillions of microscopic organisms, a vast community of bacteria that helps digest food, trains the immune system, and protects the body from invaders. When this community falls out of balance, a state scientists call dysbiosis, it can lead to serious health problems. For decades, researchers have suspected that this imbalance plays a role in how the body reacts to medications, particularly those used to prevent blood clots. These drugs, known as antithrombotics, are life-saving for people with heart disease, but they carry a significant risk: they can cause bleeding in the stomach and intestines. While doctors have long known which patients are at higher risk based on age or other health conditions, the specific role of the gut bacteria in causing these bleeds has remained a mystery. The central question has been whether the bleeding itself changes the bacteria, or if the bacteria changes are actually caused by other factors, such as the medications patients take to protect their stomachs.

A team of researchers at Fuwai Hospital in Beijing set out to solve this puzzle by looking directly at the gut contents of patients. They gathered fecal samples from sixty-six people, dividing them into three groups to compare their microbial worlds. One group consisted of twenty-two patients who were taking blood-thinning medication and had suffered a gastrointestinal bleed. A second group included twenty-two patients taking the same blood-thinning drugs but who had not experienced any bleeding. The third group was a control group of twenty-two healthy individuals who were not taking any blood-thinning medication at all. The researchers used advanced sequencing technology to read the genetic code of every bacterium in the samples, creating a detailed map of the microbial communities. They also analyzed the chemical compounds produced by these bacteria to see how the gut's internal chemistry differed between the groups.

The initial look at the data revealed a striking pattern in the patients who had bled. Their gut microbiomes showed a "double-hit" signature. First, the beneficial bacteria that produce a substance called butyrate, which acts as a fuel for the gut lining and helps keep it strong, were significantly depleted. Among these missing beneficial bacteria were specific types like Anaerobutyricum hallii and Bacteroides uniformis. Second, the gut of the bleeding patients was enriched with opportunistic pathogens, which are bacteria that can cause trouble when the gut environment is weakened. These included Enterococcus species and Staphylococcus aureus. The chemical analysis showed that the gut's ability to process certain substances, such as arachidonic acid and caffeine, was also reduced in the bleeding group. At first glance, it appeared that the bleeding event itself had wiped out the good bacteria and allowed the bad ones to take over.

However, the researchers dug deeper to see if this pattern was truly caused by the bleeding or by something else. In clinical practice, patients who experience gastrointestinal bleeding are almost always prescribed proton pump inhibitors, or PPIs, to reduce stomach acid and help the lining heal. The team noticed that the patients who had bled were much more likely to be taking these acid-reducing drugs than the patients who were on blood thinners but had not bled. To test if the PPIs were the real culprit behind the microbial changes, the researchers used statistical models to adjust for this and other factors, such as the type of blood thinner used and the presence of a common stomach infection.

When they accounted for the use of PPIs, the story changed completely. The distinct microbial signatures that seemed to point to bleeding disappeared. The specific bacteria that were missing or present in excess were no longer statistically linked to the bleeding event itself once the influence of the acid-reducing medication was removed. The researchers found that the same microbial shifts—specifically the loss of butyrate-producing bacteria and the rise of opportunistic pathogens—were seen in patients who were taking PPIs, regardless of whether they had bled. In fact, a computer model trained to distinguish between patients who had bled and those who had not performed no better than a model trained simply to distinguish between patients who took PPIs and those who did not.

The study concludes that the gut microbial changes observed in patients with antithrombotic-related bleeding are not a direct result of the bleeding itself. Instead, these changes are explained by the concomitant use of proton pump inhibitors, which are frequently prescribed to manage the bleeding. The "double-hit" fingerprint of missing beneficial bacteria and extra harmful ones is a side effect of the treatment for the bleed, not the cause of the bleed. This finding is crucial because it suggests that previous studies might have mistakenly blamed the bleeding event for microbial changes that were actually caused by the medications used to treat it. The researchers emphasize that future studies must carefully separate the effects of the disease from the effects of the drugs used to manage it, ensuring that the true causes of gut health issues are not obscured by the very treatments meant to help.